Antiprotozoal lysophospholipid analogues: A comparison of their activity against trypanosomatid parasites and tumor cells

被引：24

作者：

de Castro, SL

Santa-Rita, RM

Urbina, JA

Croft, SL

机构：

[1] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England

[2] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Celular, DUBC, BR-21045900 Rio De Janeiro, Brazil

[3] Inst Venezolano Invest Cient, Lab Quim Biol, Ctr Biofis & Bioquim, Caracas 1020A, Venezuela

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2004年 / 4卷 / 02期

关键词：

D O I：

10.2174/1389557043487439

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Lysophospholipid analogues (LPAs), originally developed as anti-cancer agents, have shown significant activity against Leishmania spp. and Trypanosoma cruzi, both in vitro and in vivo. Miltefosine, used as a topical formulation (Miltex(TM)) for metastases, was registered in 2002 for the oral treatment of visceral leishmaniasis. LPAs interfere with lipid synthesis in T. cruzi and cancer cells, but the activity is about >20-fold higher against the parasite.

引用

页码：141 / 151

页数：11

共 170 条

[1] CYTOTOXICITY OF ESTER AND ETHER LYSOPHOSPHOLIPIDS ON LEISHMANIA-DONOVANI PROMASTIGOTES [J].